Julian Harrison
Stock Analyst at BTIG
(4.38)
# 352
Out of 5,084 analysts
69
Total ratings
58.06%
Success rate
17.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Reiterates: Buy | $5 | $1.57 | +219.49% | 3 | Dec 2, 2025 | |
| TBPH Theravance Biopharma | Maintains: Buy | $25 → $40 | $18.72 | +113.73% | 3 | Nov 26, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $32 → $38 | $10.57 | +259.68% | 2 | Nov 24, 2025 | |
| RZLT Rezolute | Reiterates: Buy | $17 | $9.57 | +77.64% | 4 | Nov 20, 2025 | |
| RNAC Cartesian Therapeutics | Maintains: Buy | $42 → $44 | $6.95 | +533.09% | 2 | Nov 14, 2025 | |
| ORKA Oruka Therapeutics | Maintains: Buy | $56 → $63 | $30.98 | +103.39% | 3 | Nov 13, 2025 | |
| CNTB Connect Biopharma Holdings | Reiterates: Buy | $10 | $2.52 | +296.83% | 2 | Nov 13, 2025 | |
| LQDA Liquidia | Reiterates: Buy | $49 | $33.46 | +46.44% | 4 | Nov 4, 2025 | |
| VRDN Viridian Therapeutics | Reiterates: Buy | $61 | $32.30 | +88.85% | 4 | Nov 4, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Buy | $82 | $87.00 | -5.75% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.75 | +357.14% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $15 | $4.21 | +256.29% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $75.84 | +51.64% | 2 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $12.11 | +131.21% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $120 | $108.18 | +10.93% | 3 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 | $14.59 | +482.59% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $17.31 | +131.15% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $100 | $56.49 | +77.02% | 1 | Sep 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $33.71 | +107.65% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $42.81 | -13.57% | 3 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $18.90 | - | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $44.54 | - | 2 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $9 | $2.04 | +342.26% | 5 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $2.95 | +171.19% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.38 | +2,005.26% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.78 | +19,118.45% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $481.52 | - | 2 | Feb 11, 2022 |
Akebia Therapeutics
Dec 2, 2025
Reiterates: Buy
Price Target: $5
Current: $1.57
Upside: +219.49%
Theravance Biopharma
Nov 26, 2025
Maintains: Buy
Price Target: $25 → $40
Current: $18.72
Upside: +113.73%
Cullinan Therapeutics
Nov 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $10.57
Upside: +259.68%
Rezolute
Nov 20, 2025
Reiterates: Buy
Price Target: $17
Current: $9.57
Upside: +77.64%
Cartesian Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $42 → $44
Current: $6.95
Upside: +533.09%
Oruka Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $56 → $63
Current: $30.98
Upside: +103.39%
Connect Biopharma Holdings
Nov 13, 2025
Reiterates: Buy
Price Target: $10
Current: $2.52
Upside: +296.83%
Liquidia
Nov 4, 2025
Reiterates: Buy
Price Target: $49
Current: $33.46
Upside: +46.44%
Viridian Therapeutics
Nov 4, 2025
Reiterates: Buy
Price Target: $61
Current: $32.30
Upside: +88.85%
Protagonist Therapeutics
Oct 28, 2025
Reiterates: Buy
Price Target: $82
Current: $87.00
Upside: -5.75%
Oct 16, 2025
Reiterates: Buy
Price Target: $8
Current: $1.75
Upside: +357.14%
Oct 13, 2025
Maintains: Buy
Price Target: $55 → $15
Current: $4.21
Upside: +256.29%
Oct 9, 2025
Reiterates: Buy
Price Target: $115
Current: $75.84
Upside: +51.64%
Oct 9, 2025
Initiates: Buy
Price Target: $28
Current: $12.11
Upside: +131.21%
Oct 7, 2025
Maintains: Buy
Price Target: $112 → $120
Current: $108.18
Upside: +10.93%
Sep 29, 2025
Downgrades: Neutral
Price Target: $85
Current: $14.59
Upside: +482.59%
Sep 29, 2025
Reiterates: Buy
Price Target: $40
Current: $17.31
Upside: +131.15%
Sep 19, 2025
Reiterates: Buy
Price Target: $100
Current: $56.49
Upside: +77.02%
Sep 16, 2025
Reiterates: Buy
Price Target: $70
Current: $33.71
Upside: +107.65%
Sep 12, 2025
Maintains: Buy
Price Target: $30 → $37
Current: $42.81
Upside: -13.57%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $18.90
Upside: -
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $44.54
Upside: -
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $2.04
Upside: +342.26%
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $2.95
Upside: +171.19%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.38
Upside: +2,005.26%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.78
Upside: +19,118.45%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $481.52
Upside: -